NCT05332067View on ClinicalTrials.gov

Omalizumab Before Onset of Exacerbations

PHASE2RecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

May 1, 2022

Primary Completion Date

January 1, 2028

Study Completion Date

March 1, 2028

Conditions
Asthma in ChildrenAtopyViral Upper Respiratory Infection
Interventions
DRUG

Omalizumab

"Omalizumab dose for each specific participant is based on that participant's weight and total IgE level. Omalizumab is provided by the manufacturer in two strengths:~• For Injection: 75 mg/0.5 mL and 150 mg/mL solution in a single-dose prefilled syringe"

DRUG

Placebo

Matching placebo for omalizumab will be provided in 0.5 mL and 1 mL solution for injection in pre-filled syringes.

Trial Locations (1)

20010

RECRUITING

Children's National Hospital, Washington D.C.

Sponsors
All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Children's National Research Institute

OTHER